Understanding Brain Changes After Radiation for Brain Tumors
This study is looking at how radiation therapy for primary brain tumors (like glioma, meningioma, and schwannoma) affects the brain over time. Researchers will use special MRI scans to measure changes in brain volume and other features, and compare these changes to how your thinking and memory (neurocognition) are affected. The goal is to better understand which parts of the brain are most sensitive to radiation so that future treatments can be designed to protect them. You might be able to join if you are 18 to 99 years old, have a primary brain tumor, and are planning to receive radiation therapy. This is an observational study, meaning researchers will be watching and collecting information, not giving a new treatment. The study aims to enroll 300 participants.
- Study design
- This is an observational study that will enroll 300 participants. It is not testing a new treatment, but rather observing changes in patients receiving standard radiation therapy.
- What's involved
- You would undergo neurocognitive assessments and MRI scans at baseline (before treatment), and then again at 3, 6, and 12 months after treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months after their radiation treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Longitudinal changes in imaging biomarker volume (cc) from volumetric MR imagingbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To measure longitudinal changes in volume (cc) from volumetric MR imaging
- Longitudinal changes in imaging biomarker mean diffusivity (MD) in white matter from DTI imagingbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To measure longitudinal changes in MD (mm squared/second) from DTI imaging
- Longitudinal changes in imaging biomarker fractional anisotropy (FA) in white matter from DTI imagingbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To measure longitudinal changes in FA (unitless index between 0 and 1) from DTI imaging
- Change in Memory after RTbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To evaluate the change from baseline to post-RT verbal memory performance when performing fractionated partial brain RT. Verbal memory outcomes and measurements include: Hopkins Verbal Learning Test-Revised (HVLT-R)-Immediate, Delayed Recall. Brief Visuospatial Memory Test-Revised (BVMT-R)- Total, Delayed Recall Scale of scores is: Hopkins Verbal Learning Test-Revised (HVLT-R)-Immediate, Delayed Recall: 0-36 for Immediate, 0-12 for Delayed. For both tests, higher scores indicate better performance. Brief Visuospatial Memory Test-Revised (BVMT-R)- Total, Delayed Recall: l: 0-36 for Immediate, 0-12 for Delayed. For both tests, higher scores indicate better performance.
- Change in Executive Functioning after RTbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To evaluate the change from baseline to post-RT executive functioning performance when performing fractionated partial brain RT. Executive functioning outcomes and measurements include: Controlled Oral Word Association Test (COWA): letter fluency, Trail Making Test Part B (TMT-B). Scale of scores is: Controlled Oral Word Association Test (COWA): letter fluency: 0- no upper limit. Higher score indicates better performance Trail Making Test Part B (TMT-B): 0-240. Higher score indicates poorer performance
- Change in Attention/Processing Speed after RTbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To evaluate the change from baseline to post-RT Attention/Processing Speed performance when performing fractionated partial brain RT. Attention/Processing Speed outcomes and measurements include: Trail Making Test Part A (TMT-A) Scale of scores is: Trail Making Test Part A (TMT-A): 0-240. Higher score indicates poorer performance.
- Change in Language functioning after RTbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To evaluate the change from baseline to post-RT Language performance when performing fractionated partial brain RT in patients with primary brain tumor. Language outcomes and measurements include: Boston Naming Test (BNT), Controlled Oral Word Association Test (COWA): category fluency Scale of scores is: Boston Naming Test (BNT): 0-60 Controlled Oral Word Association Test (COWA): category fluency: 0-no upper limit. For both tests, higher score indicates better performance.
- Change in Fine Motor Skills after RTbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To evaluate the change from baseline to post-RT Fine Motor Skills performance when performing fractionated partial brain RT in patients with primary brain tumor. Fine Motor Skills outcomes and measurements include: Trail Making Test Motor Speed; Grooved Pegboard Test
- Change in health-related quality of life (hrQoL) from baseline to 5 years after RTbaseline (pre-treatment), 3 months, 6 months, 12 months post-treatment
To evaluate the change from baseline to post-RT health-related quality of life (hrQoL) when performing fractionated partial brain RT in patients with primary brain tumor. Quality of life outcomes and measurements include: Beck Depression inventory II (BDI II), Beck Anxiety Inventory (BAI) and FACT-BR (Functional Assessment of Cancer Therapy - Brain). FACT-BR (Functional Assessment of Cancer Therapy - Brain) higher scores on each subscale indicate greater hrQoL.